2023
Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg
Kelly A, Arslanian S, Hesse D, Iversen A, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff A. Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg. Obesity 2023, 31: 2139-2149. PMID: 37196421, DOI: 10.1002/oby.23808.Peer-Reviewed Original ResearchConceptsWeekly subcutaneous semaglutideBMI categoriesSubcutaneous semaglutideWeek 68Glucagon-like peptide-1 receptor agonistsObesity thresholdPeptide-1 receptor agonistsHigh-intensity physical activityObesity class IIIOverweight BMI categoryLogistic regression modelsOverweight BMIReceiving placeboTeens trialLifestyle interventionReceptor agonistPhysical activityPlaceboBMISemaglutideParticipants' BMIClass IIIOverall populationPhase 3aHealthy nutritionTirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad N, Bunck M, Benabbad I, Zhang X, investigators S, Abalos F, Manghi F, Zaidman C, Vico M, Aizenberg D, Costanzo P, Serra L, MacKinnon I, Hissa M, Vidotti M, Saraiva J, Alves B, Franco D, Moratto O, Murthy S, Goyal G, Yamasaki Y, Sato N, Inoue S, Asakura T, Shestakova M, Khaykina E, Troshina E, Vorokhobina N, Ametov A, Tu S, Yang C, Lee I, Huang C, Ou H, Freeman G, Machineni S, Klein K, Sultan S, Parsa A, Otero-Martinez J, Gonzalez A, Bhargava A, Brian S, Ince C, Plantholt S, Cole J, Lacour A, Vega D, de Souza J, Rohlf J, St. John R, Horowitz B, Audish H, Galindo R, Umpiperrez G, Ard J, Curtis B, Garvey W, Fraser N, Mandry J, Mohseni R, Mayfield R, Powell T, Vance C, Ong S, Lewy-Alterbaum A, Murray A, Al-Karadsheh A, Yacoub T, Roberts K, Fried D, Rosenstock J, Pulla B, Bode B, Frias J, Klaff L, Brazg R, Van J, Tan A, Briskin T, Rhee M, Chaicha-Brom T, Hartley P, Nunez L, Cortes-Maisonet G, Soucie G, Hsia S, Jones T. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023, 402: 613-626. PMID: 37385275, DOI: 10.1016/s0140-6736(23)01200-x.Peer-Reviewed Original ResearchConceptsType 2 diabetesBody mass indexTreatment discontinuationAdverse eventsBodyweight reductionWeight managementGlucagon-like peptide-1 receptor agonistsInteractive web response systemPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideComputer-generated random sequenceFrequent adverse eventsPlacebo-controlled trialSerious adverse eventsIncretin-based therapiesPhase 3 trialWeb response systemTreatment of obesityWeekly tirzepatideCoprimary endpointsRescue therapySafety endpointWeek 72Safety profileStudy treatmentRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff A, Du Y, Lou J, Gurbuz S, Thomas M, Hartman M, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet 2023, 402: 529-544. PMID: 37385280, DOI: 10.1016/s0140-6736(23)01053-x.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic polypeptideType 2 diabetesGLP-1 receptor agonistsEscalation groupPhase 2 trialReceptor agonistDulaglutide groupPlacebo groupStudy treatmentGLP-1Interactive web response systemModerate gastrointestinal adverse eventsType 2 diabetes managementCurrent consensus guidelinesGastrointestinal adverse eventsWeb response systemPhase 1 studyStudy site personnelHealth care centersGlucagon receptor agonistPhase 3 programRange of dosesPhase 2 dataBaseline HbAGlycaemic targets
2021
COVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity Society
Butsch WS, Hajduk A, Cardel MI, Donahoo WT, Kyle TK, Stanford FC, Zeltser LM, Kotz CM, Jastreboff AM. COVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity Society. Obesity 2021, 29: 1575-1579. PMID: 34212511, PMCID: PMC8441899, DOI: 10.1002/oby.23251.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineObesity SocietyCOVID-19-associated hospitalizationPosition statementEfficacy of vaccinesSARS-CoV-2Pfizer-BioNTechAvailable vaccinesUS FoodDrug AdministrationObesityVaccineEmergency useHigh efficacyPeer-reviewed literatureScientific evidenceCOVID-19EfficacyTime of publicationBriefing documentsDefinitive wayHospitalizationPatientsVaccinationAdministrationAddressing psychosocial health in the treatment and care of adolescents with obesity
Jebeile H, Cardel MI, Kyle TK, Jastreboff AM. Addressing psychosocial health in the treatment and care of adolescents with obesity. Obesity 2021, 29: 1413-1422. PMID: 34431234, DOI: 10.1002/oby.23194.Peer-Reviewed Original ResearchConceptsPsychosocial healthPsychosocial outcomesMajority of adolescentsCare of adolescentsBody imagePsychological supportPsychosocial impactObesity treatment interventionsAdolescentsTreatment interventionsSelf-directed weight lossFuture researchPsychosocial comorbiditiesReduced symptomsWeight management optionsMulticomponent interventionWeight lossFurther weight gainQuality of lifeTreatment servicesObesity treatmentImpact of interventionsInterventionAntiobesity pharmacotherapiesObesity care
2019
Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
Srivastava G, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, Pratt JSA, Bolling C, Michalsky MP, Cook S, Lenders CM, Apovian CM. Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity. Obesity 2019, 27: 190-204. PMID: 30677262, PMCID: PMC6449849, DOI: 10.1002/oby.22385.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIntensive lifestyle interventionObesity pharmacotherapyLifestyle interventionSevere obesityPrediabetes/type 2 diabetesObesity-related comorbid diseasesNonalcoholic fatty liver diseasePediatric primary care providersIntensive lifestyle modificationFatty liver diseaseMore effective treatment strategiesObstructive sleep apneaEffective treatment optionPrimary care providersType 2 diabetesEffective treatment strategiesLifestyle modificationPharmacotherapy optionsBariatric surgeryComorbid diseasesLiver diseaseSleep apneaTreatment algorithmExcess adiposityInformed consent regulations
2016
Utility of Psychological Screening of Young Adults with Type 1 Diabetes Transitioning to Adult Providers
Quinn SM, Ambrosino JM, Doyle EA, Weyman K, Tamborlane WV, Jastreboff AM. Utility of Psychological Screening of Young Adults with Type 1 Diabetes Transitioning to Adult Providers. Endocrine Practice 2016, 22: 1104-1110. PMID: 27295017, DOI: 10.4158/ep151190.or.Peer-Reviewed Original ResearchConceptsChart reviewEating Problem SurveyDiabetes distressAdditional patientsYoung adultsDepressive symptomsProblem SurveyPoor glycemic controlDiabetes Eating Problem SurveyBody mass indexDiabetes Distress ScalePatient Health QuestionnaireType 1 diabetesTransition clinicGlycemic controlMass indexPHQ-8Formal screeningAdult providersGlycated hemoglobinSymptomatic depressionAdult careHealth QuestionnaireMetabolic controlPatientsAltered Brain Response to Drinking Glucose and Fructose in Obese Adolescents
Jastreboff AM, Sinha R, Arora J, Giannini C, Kubat J, Malik S, Van Name MA, Santoro N, Savoye M, Duran EJ, Pierpont B, Cline G, Constable RT, Sherwin RS, Caprio S. Altered Brain Response to Drinking Glucose and Fructose in Obese Adolescents. Diabetes 2016, 65: 1929-1939. PMID: 27207544, PMCID: PMC5384636, DOI: 10.2337/db15-1216.Peer-Reviewed Original ResearchConceptsObese adolescentsLean adolescentsGlucose ingestionInsulin levelsBrain perfusionBrain regionsSugar-sweetened beverage consumptionAltered brain responsesHedonic brain regionsHippocampal blood flowFurther weight gainFructose ingestionAcyl ghrelinAttenuated suppressionFructose consumptionPerfusion responseBlood flowBrain adaptationBeverage consumptionGreater perfusionPerfusionVentral striatumFunctional MRIWeight gainIngestion
2015
Blunted suppression of acyl‐ghrelin in response to fructose ingestion in obese adolescents: The role of insulin resistance
Van Name M, Giannini C, Santoro N, Jastreboff AM, Kubat J, Li F, Kursawe R, Savoye M, Duran E, Dziura J, Sinha R, Sherwin RS, Cline G, Caprio S. Blunted suppression of acyl‐ghrelin in response to fructose ingestion in obese adolescents: The role of insulin resistance. Obesity 2015, 23: 653-661. PMID: 25645909, PMCID: PMC4548801, DOI: 10.1002/oby.21019.Peer-Reviewed Original ResearchConceptsAcyl ghrelinObese insulinGlucose ingestionInsulin resistanceObese adolescentsCross-over designFructose ingestionGut hormonesChildhood obesityInsulin sensitivityFructose consumptionEffect of glucoseDiminished suppressionRandom orderIngestionObesityPYYAdolescentsInsulinSuppression differencesGlucoseMinutesResponseGhrelinOIR
2014
Leptin Is Associated With Exaggerated Brain Reward and Emotion Responses to Food Images in Adolescent Obesity
Jastreboff AM, Lacadie C, Seo D, Kubat J, Van Name MA, Giannini C, Savoye M, Constable RT, Sherwin RS, Caprio S, Sinha R. Leptin Is Associated With Exaggerated Brain Reward and Emotion Responses to Food Images in Adolescent Obesity. Diabetes Care 2014, 37: 3061-3068. PMID: 25139883, PMCID: PMC4207200, DOI: 10.2337/dc14-0525.Peer-Reviewed Original ResearchConceptsLow-calorie foodsBrain responsesFood imagesEmotion processingEmotion responsesAdolescent brainNeural responsesNeural activationHigh-calorie food consumptionFood cravingsNeural alterationsBrain rewardFunctional MRIAdolescent obesityRisk of overconsumptionAdolescentsObesity-related metabolic changesEndogenous leptin levelsFood advertisingMetabolic changesYouthDevelopment of obesityType 2 diabetesLean adolescentsNation's youthSex differences in the association between dietary restraint, insulin resistance and obesity
Jastreboff AM, Gaiser EC, Gu P, Sinha R. Sex differences in the association between dietary restraint, insulin resistance and obesity. Eating Behaviors 2014, 15: 286-290. PMID: 24854820, PMCID: PMC4032476, DOI: 10.1016/j.eatbeh.2014.03.008.Peer-Reviewed Original ResearchConceptsBody mass indexInsulin resistanceMass indexRestrained eatingHomeostatic model assessmentSex differencesObese weight categoriesEating Behavior QuestionnaireEventual weight gainDutch Eating Behavior QuestionnaireHOMA-IRPlasma insulinObservational studyModel assessmentAbstractTextWeight categoriesWeight gainDietary restraintLarge community sampleFood consumptionWomenMenAIMSCommunity sampleBehavior Questionnaire
2013
Comparison of BMI and Physical Activity Between Old Order Amish Children and Non-Amish Children
Hairston KG, Ducharme JL, Treuth MS, Hsueh WC, Jastreboff AM, Ryan KA, Shi X, Mitchell BD, Shuldiner AR, Snitker S. Comparison of BMI and Physical Activity Between Old Order Amish Children and Non-Amish Children. Diabetes Care 2013, 36: 873-878. PMID: 23093661, PMCID: PMC3609522, DOI: 10.2337/dc12-0934.Peer-Reviewed Original ResearchConceptsMin/dayPhysical activityOld Order AmishNutrition Examination Survey dataBMI z-scoreVigorous physical activityComparison of BMIHip-worn accelerometersOld Order Amish childrenNon-Hispanic white populationPediatric overweightMean BMIExcess weightNational HealthLong-term protectionLow prevalenceES groupNHANES estimatesChildhood factorsZ-scorePA levelsBMIDiabetesAnthropometric dataWhite population
2007
Three Faces of Hypothalamic Tumors
Jastreboff A, Sherr J. Three Faces of Hypothalamic Tumors. Journal Of Pediatric Endocrinology And Metabolism 2007, 20: 471-472. PMID: 17550209, DOI: 10.1515/jpem.2007.20.4.471.Peer-Reviewed Case Reports and Technical Notes